

## ASX ANNOUNCEMENT

### Case Studies of PeriCoach published in Peer Reviewed Urology Journal

**19 May 2016: Brisbane, Australia** – Analytica Ltd (ASX:ALT) manufacturer of the PeriCoach® System is pleased to announce the publication of case studies describing pelvic floor training with PeriCoach in the Urologic Nursing Journal of the US Society of Urologic Nurses and Associates.

Clinical support and publication in a leading peer review journal is a significant milestone for the Company and is a direct reflection of executing its strategy to obtain clinical evidence of PeriCoach.

The journal articles are authored by US Nurse Practitioner (NP) Julie Starr and Physiotherapist (PT) Beth Shelley. The articles are based on two separate case studies which were conducted to demonstrate the efficacy and ease of the use PeriCoach in the treatment of common pelvic floor dysfunctions such as urinary incontinence and pelvic organ prolapse, as well as the emotional and lifestyle benefits of restoring pelvic floor strength.

These outcomes are a direct result of the Company's US Early Adopter Program in which leaders in pelvic health were encouraged to utilise PeriCoach in practice with patients currently engaged in a pelvic floor rehabilitation program.

In both cases studies, PeriCoach was demonstrated to be an easy-to-use, affordable and effective non-surgical home training option for strengthening pelvic floor muscles and decreasing symptoms of UI and POP.

- The case reported by Julie Starr, APRN, FNP, Women's Health Care, University of Missouri Healthcare, describes the experience of an athletic 37-year-old woman seeking treatment for symptoms of stress urinary incontinence.
- The Case reported by Beth Shelley, PT, DPT, WCS, BCB-PMD, describes the experience of a 66-year-old woman with Pelvic Organ Prolapse (POP) and urinary incontinence who performed at-home PFME with the assistance of PeriCoach.

Analytica CEO Geoff Daly said – "The publication of these case studies is a great endorsement for PeriCoach and is our greatest differentiator to other players in the incontinence market. It demonstrates that we are on the right path with our strategy in becoming the trusted solution for incontinence for clinicians and women."

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale in Australia and New Zealand, UK and Ireland, and in the US by prescription.

Shareholders can access both case studies via -

[http://www.pericoach.com/wp-content/uploads/2016/05/unj\\_ma16\\_05\\_STARR\\_FINAL.pdf](http://www.pericoach.com/wp-content/uploads/2016/05/unj_ma16_05_STARR_FINAL.pdf)

[http://www.pericoach.com/wp-content/uploads/2016/05/unj\\_ma16\\_04\\_BShelly\\_FINAL.pdf](http://www.pericoach.com/wp-content/uploads/2016/05/unj_ma16_04_BShelly_FINAL.pdf)



For more information, please contact: [investorrelations@analyticamedical.com](mailto:investorrelations@analyticamedical.com)

For more information about the PeriCoach System, visit: [www.PeriCoach.com](http://www.PeriCoach.com)

For more information about Analytica, visit [www.AnalyticaMedical.com](http://www.AnalyticaMedical.com)

Follow us on:



### About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale in Australia and New Zealand, UK and Ireland, and in the USA by prescription.

